1 citations,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
185 citations,
August 2005 in “Autoimmunity Reviews” Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.
[object Object] 
127 citations,
January 2015 in “Journal of Biological Rhythms” The skin's internal clock affects healing, cancer risk, aging, immunity, and hair growth, and disruptions can harm skin health.
59 citations,
September 2008 in “Experimental dermatology” Both mouse and rat models are effective for testing alopecia areata treatments.
48 citations,
May 2008 in “Drug Discovery Today: Disease Mechanisms” Hair follicles offer promising targets for delivering drugs to treat hair and skin conditions.
33 citations,
December 2005 in “Archives of dermatology” Alefacept showed some effectiveness for alopecia areata but needs more research.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
16 citations,
June 2017 in “Advances in Therapy” New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.
15 citations,
April 2011 in “Pediatric Nephrology” New treatments for lupus show promise, but more research is needed, especially for children.
11 citations,
July 2014 in “Gene” The S250C variant in a gene may cause autoimmunity and immunodeficiency by impairing protein function.
6 citations,
April 2017 in “Experimental dermatology” CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.
[object Object] 
2 citations,
October 2015 in “Human Gene Therapy” The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.
May 2024 in “Frontiers in Immunology” This mini-review examines the role of type-2 immunity in type-1-related skin inflammatory diseases, such as alopecia areata (AA), vitiligo, and localized scleroderma (LS). It reveals that while type-1 immunity is traditionally associated with these conditions, type-2 immunity also plays a significant role. In LS, type-2 cytokines like IL-4 and IL-13 are linked to fibrosis, and in AA, elevated type-2 markers suggest involvement in disease pathogenesis. The review highlights the potential of treatments targeting type-2 responses, such as JAK inhibitors and therapies focusing on the IL-4/IL-13 axis, which show promise in specific patient subsets. Further research is needed to understand whether type-2 immunity is protective or detrimental in these diseases, which could improve patient stratification for targeted therapies.
December 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” Aged individuals heal wounds less effectively due to specific immune cell issues.
November 2022 in “CARDIOMETRY” A group has developed therapies that show promise for treating cancer and various other conditions.
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” HDAC inhibitors, like Vorinostat and Entinostat, can help regrow hair in alopecia areata.
April 2016 in “Plastic and reconstructive surgery. Global open” The supplement highlighted advancements and challenges in plastic and reconstructive surgery, including the impact of smoking, chemotherapy, and new treatments like Tafluprost for hair loss.
4 citations,
October 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.
79 citations,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” Alopecia areata may be treated by restoring hair follicle immune privilege and adjusting immune responses.
29 citations,
April 2000 in “Journal of histochemistry and cytochemistry/The journal of histochemistry and cytochemistry” ICAM-1 helps regulate hair growth cycles and skin remodeling.
15 citations,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
717 citations,
June 2010 in “Nature” Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.
181 citations,
February 2019 in “Cell” Innate lymphoid cells help control skin bacteria by regulating sebaceous glands.
23 citations,
December 2021 in “Frontiers in Immunology” IL-1 family cytokines are crucial for skin defense and healing, but their imbalance can cause skin diseases.
1 citations,
June 2023 in “Genes” Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
1 citations,
April 2023 in “Frontiers in Immunology” New treatments for hair loss from alopecia areata may include targeting immune cells, using stem cells, balancing gut bacteria, applying fatty acids, and using JAK inhibitors.
1 citations,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” New treatments and strategies are needed for Alopecia Areata, focusing on immune response and better trial designs.
October 2024 in “Stem Cell Research & Therapy” CGF therapy may effectively treat psoriasis by reducing inflammation.